Methods of metabolizing metopimazine and its salts
AssigneeNeurogastrx, Inc.
InventorsRobert W. Busby, Cyril De Colle
Life of this patent
Estimating the term…
Abstract
Provided herein is process of preparing metopimazine acid by reacting metopimazine, or a pharmaceutically acceptable salt thereof, with human microsomal liver amidase. Also provided herein are methods of treating gastroparesis in a human subject in need thereof with metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent which is not metabolized by human microsomal liver amidase and/or human liver cytosolic aldehyde oxidase.
Claims91
A process of preparing metopimazine acid,
- comprising contacting metopimazine,
- or a pharmaceutically acceptable salt thereof, with human microsomal liver amidase.
A process of preparing metopimazine acid, comprising contacting metopimazine, or a pharmaceutically acceptable salt thereof, with human liver cytosolic aldehyde oxidase.
A method of treating gastroparesis in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A method of treating gastroparesis in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
A method of treating nausea associated with gastroparesis in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A method of treating nausea associated with gastroparesis in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
A method of treating vomiting associated with gastroparesis in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A method of treating vomiting associated with gastroparesis in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
A method of improving gastric emptying in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A method of improving gastric emptying in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
A method of treating functional and motility disorders of the GI tract in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A method of treating functional and motility disorders of the GI tract in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
A method of treating an enteric nervous system disorder in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A method of treating an enteric nervous system disorder in a human subject in need thereof, comprising administering to the subject metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
A pharmaceutical composition comprising metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human microsomal liver amidase.
A pharmaceutical composition comprising metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent, wherein the additional therapeutic agent is not metabolized by human liver cytosolic aldehyde oxidase.
Dependencies are inferred from the claim text.